µ¼Ê¦ÐÕÃû£º¸¶²ÊÔÆ
ÐÔ±ð£ºÅ®
ÈËÆøÖ¸Êý£º529
ËùÊôԺУ£ºÕã½Àí¹¤´óѧ
ËùÊôԺϵ£ºÉúÃü¿ÆÑ§Ñ§Ôº
Ö°³Æ£º¸±½ÌÊÚ
µ¼Ê¦ÀàÐÍ£º
ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÉúÎïѧ
Ñо¿ÁìÓò£º 1.Ö×ÁöÉúÎïÖÎÁÆ2.С·Ö×Ó°ÐÏòÒ©Ñз¢ÓëÖ×Áö°ÐÏòÖÎÁÆ3.¶àëÄÒ©Àíѧ
Ñо¿ÁìÓò£º 1.Ö×ÁöÉúÎïÖÎÁÆ2.С·Ö×Ó°ÐÏòÒ©Ñз¢ÓëÖ×Áö°ÐÏòÖÎÁÆ3.¶àëÄÒ©Àíѧ [ÊÕÆð]
ͨѶ·½Ê½ :
°ì¹«µç»°£º**
ͨѶµØÖ·£ºº¼ÖÝÏÂɳ¸ß½ÌÔ°Çø2ºÅ´ó½Ö928ºÅ
¸öÈ˼òÊö :
¸¶²ÊÔÆ ¸±½ÌÊÚ£¬²©Ê¿£¬ÉúÎﻯѧÓë·Ö×ÓÉúÎïѧöλÔÓéÀֵǼÈë¿ÚÏÂÔØ¡¢Ï¸°ûÉúÎïѧöλÔÓéÀֵǼÈë¿ÚÏÂÔØË¶Ê¿Éúµ¼Ê¦£¬Õã½Àí¹¤´óѧÇàÄê¹Ç¸É½Ìʦ¡£Ö÷³Ö½áÌâ¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ðÇàÄê»ù½ðºÍÃæÉÏÏîÄ¿¸÷Ò»ÏÒÔ¼°Õã½Ê¡×ÔÈ»¿ÆÑ§»ù½ðÃæÉÏÏîĿһÏÖ÷³ÖÔÚÑйú¼Ò×ÔÈ»¿ÆÑ§»ù½ðÃæÉÏÏîĿһÏ·¢±íSCIÂÛÎÄ26ƪ£¬ÆäÖаüÀ¨SCIÒ»ÇøTOPÆÚ¿¯ÔÚÄڵĵÚÒ»/ͨѶ×÷ÕßSCIÂÛÎÄ18ƪ£¬É걨¹ú¼Ò·¢Ã÷רÀû12ÏÆäÖÐ6ÏîÒÑÊÚȨ£¬2ÏîÒÑתÈ᣸¶²ÊÔÆÀÏʦ2012ÄêÈëÑ¡Õã½Àí¹¤´óѧ¹ú¼Ê»¯¡°ÖÐÇàÄê°Î¼âÈ˲š±ÒýÁì¼Æ»®£¬2013ÄêÈëÑ¡Õã½Ê¡µÚÒ»Åú¡°ÇàÄê¿ÆÑ§¼Ò¡±ÅàÑø¼Æ»®£¬2014ÄêÈëÑ¡Õã½Ê¡¡°ÐÂÊÀ¼Í151È˲ʤ³Ì¡±ÅàÑø¼Æ»®£¬2015Äê»ñÕã½Ê¡×ª»¯Ò½Ñ§Ñ§»áÓÅÐãÀíÊÂÈÙÓþ³ÆºÅ£¬2016Äê»ñ½ÌÓý²¿°ä·¢µÄ»ôÓ¢¶«½ÌÓý»ù½ð»áµÚÊ®Îå½ì¸ßµÈԺУÇàÄê½Ìʦ½±£¬2017ÄêÈëÑ¡Õã½Ê¡Å®¿Æ¼¼¹¤×÷ÕßлáÊ×Åú»áÔ±¡£
Ö÷Ҫѧϰ¹¤×÷¾Àú
1999.09~2003.06 À¼ÖÝ´óѧÉúÃü¿ÆÑ§Ñ§ÔºÉúÎïѧ»ùµØ°à£¬Ñ§Ê¿£¨°àÖ÷ÈΣºÕÅÓ÷½ÌÊÚ£©
2003.09~2008.06 À¼ÖÝ´óѧÉúÃü¿ÆÑ§Ñ§ÔºÉúÎﻯѧÓë·Ö×ÓÉúÎïѧÑо¿Ëù£¬Ë¶²©Á¬¶Á£¬Àíѧ²©Ê¿ £¨µ¼Ê¦£ºÍõÈñ½ÌÊÚ£©
2008.12~2010.10 Õã½Àí¹¤´óѧ£¬ÉúÃü¿ÆÑ§Ñ§Ôº½²Ê¦
2010.10~2013.10 Õã½Àí¹¤´óѧ£¬¸±Ñо¿Ô±£¬Ë¶Ê¿Éúµ¼Ê¦
2013.10~ÖÁ½ñ Õã½Àí¹¤´óѧ£¬¸±½ÌÊÚ£¬Ë¶Ê¿Éúµ¼Ê¦
2013.10~2014.01 Ä«¶û±¾ Peter MacCallum Cancer Centre ½øÐзÃÎÊѧϰ £¨µ¼Ê¦£ºRick Pearson ½ÌÊÚ£©
2017.08-2018.08 ÃÀ¹úUCSF·ÃÎÊѧÕߣ¨µ¼Ê¦Lei Wang½ÌÊÚ£©
Ö÷ҪѧÊõ¼°Éç»á¼æÖ°
2013Äê9ÔÂ25ÈÕ±»Æ¸ÎªÕã½Àí¹¤´óѧ¿ÆÑ§¼¼ÊõлáѧÊõ²¿¸±²¿³¤
2014Äê4ÔÂ02ÈÕ±»Æ¸ÎªÕã½Ê¡×ª»¯Ò½Ñ§Ñ§»á¿ÆÆÕÓë×Éѯ·Ö»á¸±»á³¤
2014Äê4ÔÂ02ÈÕ±»Æ¸ÎªÕã½Ê¡×ª»¯Ò½Ñ§Ñ§»áÇàί»áίԱ
2014Äê10ÔÂ10ÈÕ±»Æ¸ÎªÕã½Ê¡×ª»¯Ò½Ñ§Ñ§»áÀíÊÂ/ÃØÊ飻Õã½Ê¡Ï¸°ûÉúÎïѧ»áÀíÊÂ/ÃØÊé
2015Äê10ÔÂ9ÈÕ±»Æ¸ÎªÖйúת»¯Ò½Ñ§ÁªÃËÀíÊÂ/¸±ÃØÊ鳤
2015Äê10ÔÂ22ÈÕ±»Æ¸ÎªÖйúÒ½Ò©ÉúÎï¼¼Êõлáת»¯Ò½Ñ§·Ö»áίԱ/ÃØÊé
2017Äê5ÔÂ9ÈÕÈëÑ¡Õã½Ê¡Å®¿Æ¼¼¹¤×÷ÕßлáÊ×Åú»áÔ±
¿ÆÑй¤×÷ :
×÷ΪÏîÄ¿¸ºÔðÈ˽áÌâ¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ðÇàÄê»ù½ðºÍÃæÉÏÏîÄ¿¸÷Ò»ÏÕã½Ê¡×ÔÈ»¿ÆÑ§»ù½ðÃæÉÏÏîĿһÏÕã½Ê¡½ÌÓýÌüÏîĿһÏÕã½Ê¡ÖØÖÐÖ®ÖØÓÅÐãÈ˲Żù½ðÒ»ÏÕã½Ê¡¸ßУÉúÎïÑ§ÖØÖÐÖ®ÖØ£¨Ò»¼¶£©Ñ§¿ÆÑ§¿Æ´øÍ·ÈËÅàÑøÏîĿһÏÖ÷³ÖÔÚÑйú¼Ò×ÔÈ»¿ÆÑ§»ù½ðÃæÉÏÏîĿһÏ×÷ΪÏîÄ¿Ö÷Òª²ÎÓëÕß²ÎÓë½áÌâÁ˶àÏî¹ú¼Ò¼¶ºÍÊ¡²¿¼¶ÏîÄ¿¡£·¢±íSCIÂÛÎÄ26ƪ£¬ÆäÖÐÒÔµÚÒ»×÷Õß/ͨѶ×÷Õß·¢±íSCIÂÛÎÄ18ƪ¡£É걨¹ú¼Ò·¢Ã÷רÀû12ÏÆäÖÐÊÚȨ¹ú¼Ò·¢Ã÷רÀû6ÏתÈùú¼Ò·¢Ã÷רÀû2Ïî¡£Ö¸µ¼Ñ§ÉúÁ¬ÐøÈý½ì»ñÌôÕ½±´óѧÉú¿ÎÍâѧÊõ×÷Æ·¾ºÈü¹úÈüÀÛ»ý´´Ð½𽱡¢Òø½±¡¢¹úÈü¶þµÈ½±¡¢Ê¡ÈüÒ»µÈ½±¡¢Ð£ÈüÌØµÈ½±µÈ¶àÖÖÈÙÓþ³ÆºÅ£»Ö¸µ¼±¾¿ÆÉú»ñ2014ÄêÕã½Ê¡´óѧÉúÉúÃü¿ÆÑ§¾ºÈüÒ»µÈ½±µÈ¶àÖÖÈÙÓþ³ÆºÅ¡£
¿ÆÑÐÏîÄ¿-×ÝÏò
1. Annexin A1µ÷¿ØNotch1/Smad2/p15ÐźÅÖá´Ù½ø¼±ÐÔËèϵ°×Ѫ²¡Ï¸°ûÔöÖ³µÄ»úÖÆÑо¿£¨ÏîÄ¿±àºÅ**£©,¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ðÃæÉÏÏîÄ¿£¬¹ú¼Ò¼¶£¬55ÍòÔª£¬2018.1-2021.12£¬ÅÅÃû1/10£¬Ö÷³ÖÔÚÑУ»
2. ²¸È鶯ÎïËÙ¼¤ëÄhemokinin-1µÄÖÐÊàÕòʹλµãºÍÕòÍ´»úÖÆÑо¿£¨ÏîÄ¿±àºÅ**£©£¬¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ðÇàÄê»ù½ð£¬¹ú¼Ò¼¶£¬21ÍòÔª£¬2011.1-2013.12£¬ÅÅÃû1/9£¬Ö÷³Ö½áÌ⣻
3. °ÐÏò×è¶ÏÉñ¾¼¤ëÄÊÜÌåÒÖÖÆ°×Ѫ²¡Ï¸°ûÉú³¤µÄ·Ö×Ó»úÖÆ¼°ÆäÔÚ°×Ѫ²¡ÖÎÁÆÖеÄDZÔÚ¼ÛÖµ£¨ÏîÄ¿±àºÅ**£©,¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ðÃæÉÏÏîÄ¿£¬¹ú¼Ò¼¶£¬30ÍòÔª£¬2015.1-2016.12£¬ÅÅÃû1/10£¬Ö÷³Ö½áÌ⣻
4. ɳÈð¶È̹ÒÖÖÆÈËÁ£ÐÔ°×Ѫ²¡Ï¸°ûÔöÖ³µÄ°Ðµãµ°°×ɸѡ¼°Æä¹¦ÄÜÑо¿£¨ÏîÄ¿±àºÅLY14C050003£©£¬Õã½Ê¡×ÔÈ»¿ÆÑ§»ù½ðÃæÉÏÏîÄ¿£¬Ê¡²¿¼¶£¬8ÍòÔª£¬2014.01-2016.12£¬ÅÅÃû1/5£¬Ö÷³Ö½áÌ⣻
5. Neurokinin Receptors¼¤¶¯¼ÁÓÕµ¼Ð¡Êóºì°×Ѫ²¡Ï¸°ûMEL·Ö»¯µÄ×÷Óü°µ÷¿ØÑо¿£¨ÏîÄ¿±àºÅY**£©£¬Õã½Ê¡½ÌÓýÌüÏîÄ¿£¬Ìü¾Ö¼¶£¬1.2ÍòÔª£¬2009.12-2011.12£¬ÅÅÃû1/6£¬Ö÷³Ö½áÌ⣻
6. Neurokinin Receptors¼¤¶¯¼ÁÔÚ¶ñÐÔÖ×Áöϸ°ûÉú³¤¹ý³ÌÖеÄ×÷Óü°Æä»úÖÆÑо¿£¨ÏîÄ¿±àºÅSWYX0903£©£¬Õã½Ê¡¡°ÖØÖÐÖ®ÖØ¡±¿ª·Å»ù½ð£¬Ê¡²¿¼¶£¬7ÍòÔª£¬2009.10-2011.10£¬ÅÅÃû2/5£¬
7. iTRAQ¼¼Êõ½áºÏLC-MS·ÖÎöSR140333ÒÖÖÆ°×Ѫ²¡Ï¸°ûÉú³¤µÄ·Ö×Ó»úÖÆÑо¿£¨ÏîÄ¿±àºÅ**306£©£¬Õã½Ê¡¡°ÖØÖÐÖ®ÖØ¡±ÓÅÐãÈ˲Żù½ð£¬Ê¡²¿¼¶£¬5ÍòÔª£¬2014.01-2015.12£¬ÅÅÃû1/5.
8. ËÙ¼¤ëÄeledoisin¶ÔѪ¹ÜÄÚÆ¤Ï¸°û¹¦ÄܵÄÓ°Ï죨ÏîÄ¿±àºÅ**-Y£©£¬Õã½Àí¹¤´óѧ¿ÆÑÐÆô¶¯»ù½ð£¬Ð£¼¶£¬2ÍòÔª£¬2009.07-2012.12£¬ÅÅÃû1/6£¬½áÌ⣻
9. »ùÓÚÉñ¾ëĶø¹¹½¨µÄÁ½ÀàÐÂÐÍÅäÌåÔÚMu°¢Æ¬ÊÜÌå¾ÛºÏÌåµÄÐźÅתµ¼ºÍÍ´¾õµ÷½ÚÖеÄÓ¦Óã¨ÏîÄ¿±àºÅ**£©£¬¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ðÖØ´óÑо¿¼Æ»®£¬¹ú¼Ò¼¶£¬50ÍòÔª£¬2009.01-2011.12£¬ÅÅÃû8/10£¬½áÌ⣻
10. 30Kµ°°×¶ÔÖ¬ÖʹýÑõ»¯ËðÉ˵ÄÈËѪ¹ÜÄÚÆ¤Ï¸°û±£»¤×÷ÓõÄÑо¿£¨ÏîÄ¿±àºÅ**£©£¬Õã½Ê¡×ÔÈ»¿ÆÑ§»ù½ð£¬Ê¡²¿¼¶£¬8ÍòÔª£¬2010.01-2012.12£¬ÅÅÃû2/5£¬½áÌ⣻
11. ¼Ò²ÏÉúÎï·´Ó¦Æ÷Éú²úµÄµ°°×Ò©ÎïBmrhGM-CSF¿Ú·þÎüÊÕ»úÖÆµÄÑо¿£¨ÏîÄ¿±àºÅY**£©£¬Õã½Ê¡×ÔÈ»¿ÆÑ§»ù½ð£¬Ê¡²¿¼¶£¬8ÍòÔª£¬2011.01-2013.12£¬ÅÅÃû3/5£¬½áÌ⣻
12. Éñ¾¼¤ëÄÊÜÌå 2 µÄÞ׿¹¼Á SR48968 ÒÖÖÆÈËÂýÐÔÁ£ÐÔ°×Ѫ²¡Ï¸°ûÉú³¤µÄ»úÖÆÑо¿£¨ÏîÄ¿±àºÅ**210£©£¬Õã½Ê¡¿Æ¼¼Ìü£¨ÐÂÃçÈ˲żƻ®£©£¬Ìü¾Ö¼¶£¬1ÍòÔª£¬Ö¸µ¼½Ìʦ1/1£¬½áÌ⣻
13. ¿¹¾úëÄAnoplin¶ÔѪ°©Ï¸°ûÉú³¤µÄÒÖÖÆ×÷Óü°Æä×÷ÓûúÖÆÑо¿£¨ÏîÄ¿±àºÅ**161£©£¬Õã½Ê¡¿Æ¼¼Ìü£¨ÐÂÃçÈ˲żƻ®£©£¬Ìü¾Ö¼¶£¬1ÍòÔª£¬Ö¸µ¼½Ìʦ1/1£¬½áÌ⣻
14. È˰×ϸ°û½éËØ-6»ùÒòµÄ¿Ë¡ÓëԺ˱í´ïÑо¿£¨ÏîÄ¿±àºÅ**130£©£¬Õã½Ê¡¿Æ¼¼Ìü£¨ÐÂÃçÈ˲żƻ®£©£¬Ìü¾Ö¼¶£¬1ÍòÔª£¬Ö¸µ¼½Ìʦ1/1£¬½áÌ⣻
15. Rat/mouse hemokinin-1ÒÖÖÆÐ¡Êóºì°×Ѫ²¡Ï¸°ûMELÔöÖ³µÄ×÷Óü°»úÖÆÑо¿£¨ÏîÄ¿±àºÅ**025£©£¬Õã½Ê¡¿Æ¼¼Ìü£¨ÐÂÃçÈ˲żƻ®£©£¬Ìü¾Ö¼¶£¬1ÍòÔª£¬Ö¸µ¼½Ìʦ1/1£¬½áÌ⣻
16. ÂýÐÔËèÐÔ°×Ѫ²¡ÂãÊóÄ£Ð͵Ĺ¹½¨¼°SR48968¶ÔÆäÖÎÁÆÐ§¹ûµÄÑо¿£¨ÏîÄ¿±àºÅ**201£©£¬Õã½Àí¹¤´óѧÑо¿Éú´´ÐÂÏîÄ¿£¬Ð£¼¶£¬0.2ÍòÔª£¬Ö¸µ¼½Ìʦ1/1£¬½áÌâ¡£
17. Éñ¾¼¤ëÄÊÜÌåÞ׿¹¼Á¶ÔСÊó¹Ç°©Í´µÄ×÷Óü°Æä»úÖÆÑо¿£¬2015Äê¹ú¼Ò¼¶´´Ð´´ÒµÑµÁ·¼Æ»®ÏîÄ¿£¬¹ú¼Ò¼¶£¬2ÍòÔª£¬Ö¸µ¼½Ìʦ1/1
18. Ó¦Óõ°°×ÖÊ×éѧ¼¼Êõɸѡ°ÐÏò×è¶ÏÉñ¾¼¤ëÄÊÜÌåºóÒÖÖÆ°×Ѫ²¡Ï¸°ûÔöÖ³µÄ°Ðµãµ°°×Ñо¿£¨ÏîÄ¿±àºÅ2014A10-A£©£¬Õã½Ê¡¸ßУÉúÎïÑ§ÖØÖÐÖ®ÖØ£¨Ò»¼¶£©Ñ§¿ÆÑ§¿Æ´øÍ·ÈËÅàÑøÏîÄ¿£¬Ê¡²¿¼¶£¬34ÍòÔª£¬1/6£¬2015.05-2015.12
19. °ÐÏò×è¶ÏÉñ¾¼¤ëÄÊÜÌåÓë½á³¦°©Ï¸°ûÉú³¤µÄ¹ØÏµÑо¿£¨ÏîÄ¿±àºÅ2015R406076£©£¬Õã½Ê¡¿Æ¼¼Ìü£¨ÐÂÃçÈ˲żƻ®£©£¬Ìü¾Ö¼¶£¬1ÍòÔª£¬Ö¸µ¼½Ìʦ1/1£¬ÔÚÑо¿£¨2015£¬Öܺޱ£©
20. Éñ¾¼¤ëÄÊÜÌåÞ׿¹¼Á¶Ô¹Ç°©Í´Ð¡ÊóµÄ×÷Óü°Æä»úÖÆÑо¿£¨ÏîÄ¿±àºÅ2015R406013£©£¬Õã½Ê¡¿Æ¼¼Ìü£¨ÐÂÃçÈ˲żƻ®£©£¬Ìü¾Ö¼¶£¬1ÍòÔª£¬Ö¸µ¼½Ìʦ1/1£¬ÔÚÑо¿£¨2015£¬ÖìÏþ´ä£©
¿ÆÑÐÏîÄ¿-ºáÏò
1. Àõ×ÓÆº×ÔÈ»±£»¤Çø´óÐÜèÖ÷ʳÖñÇøÓòÍÁÈÀø»îÐԲⶨ£¨ÏîÄ¿ºÅ£º116129A4J13450£»**-J £©£¬ºáÏò¿ÎÌ⣨Î÷»ªÊ¦·¶´óѧ£©£¬2013.12-2015.12£¬ÅÅÃû1/2£»
2. ·ä¶¾¿¹¾úëÄAnoplinÔÚʳ¹Ü°©ÖÎÁÆÖеÄÓÃ;£¨ÏîÄ¿ºÅ£º116129A4J15036£»**-J £©£¬ºáÏò¿ÎÌ⣨רÀûתÈã©£¬2015.01-2024.01£¬ÅÅÃû1/5£»
3. Éñ¾¼¤ëÄÊÜÌåÞ׿¹¼ÁÔÚÖÆ±¸¿¹°©Ò©ÎïÖеÄÓÃ;£¨ÏîÄ¿ºÅ£º116129A4J15037£»**-J £©£¬ºáÏò¿ÎÌ⣨רÀûתÈã©£¬2015.01-2024.01£¬ÅÅÃû1/5¡£
רÀû
1. רÀûÊÚȨºÅ£ºZL 2011 1 **.1£» רÀûÊÚȨÈÕ£º2012Äê10ÔÂ03ÈÕ£»ÉêÇëÈË£ºÕã½Àí¹¤´óѧ£»×¨ÀûÉêÇëºÅ£º**0.1£»×¨ÀûÉêÇëÈÕ£º2011Äê3ÔÂ23ÈÕ£»·¢Ã÷´´ÔìÃû³Æ£ºÉñ¾¼¤ëÄÊÜÌåÞ׿¹¼ÁÔÚÖÆ±¸¿¹°©Ò©ÎïÖеÄÓÃ;£»·¢Ã÷ÈË£º¸¶²ÊÔÆ ÕÔ¸¨À¥ ÕÅÊÀð¥ ÍõÓîɳ ³ÂÅÊ·å¡£ÒÑתÈÃ
2. רÀûÊÚȨºÅ£ºZL 2011 1 **.0£» רÀûÊÚȨÈÕ£º2013Äê03ÔÂ27ÈÕ£»ÉêÇëÈË£ºÕã½Àí¹¤´óѧ£»×¨ÀûÉêÇëºÅ£º**7.0£»×¨ÀûÉêÇëÈÕ£º2011Äê3ÔÂ23ÈÕ£»·¢Ã÷´´ÔìÃû³Æ£ºSR140333µÄ¿¹Ñª°©×÷Óã»·¢Ã÷ÈË£º¸¶²ÊÔÆ ÕÔ¸¨À¥ ÕÅÊÀð¥ ÍõÓîɳ ³ÂÅÊ·å¡£
3. רÀûÊÚȨºÅ£ºZL 2012 1 **.8£»×¨ÀûÊÚȨÈÕ£º2014Äê07ÔÂ16ÈÕ£»ÉêÇëÈË£ºÕã½Àí¹¤´óѧ£»×¨ÀûÉêÇëºÅ£º**0.8£»×¨ÀûÉêÇëÈÕ£º2011Äê3ÔÂ23ÈÕ£»·¢Ã÷´´ÔìÃû³Æ£ºÉñ¾¼¤ëÄÊÜÌå2µÄÞ׿¹¼ÁÔÚ°×Ѫ²¡ÖÎÁÆÖеÄÓÃ;£»·¢Ã÷ÈË£º¸¶²ÊÔÆ ÏÄÈðÁú ÕÔ¸¨À¥ ÕÅÊÀ𥠳ÂÅÊ·å ÍõÓîɳ ¡£
4. רÀûÊÚȨºÅ£ºZL 2013 1 **.7£»×¨ÀûÊÚȨÈÕ£º2014Äê11ÔÂ12ÈÕ£»×¨ÀûÉêÇëºÅ£º**7.7£»×¨ÀûÉêÇëÈÕ£º2013Äê03ÔÂ05ÈÕ£»ÉêÇëÈË£ºÕã½Àí¹¤´óѧ£»·¢Ã÷´´ÔìÃû³Æ£º·ä¶¾¿¹¾úëÄAnoplinÔÚʳ¹Ü°©ÖÎÁÆÖеÄÓÃ;£»·¢Ã÷ÈË£º¸¶²ÊÔÆ£¬Â¬Ñ࣬ÖìÀöÄÈ£¬ÕÔ¸¨À¥£¬ÕÅÊÀ𥡣ÒÑתÈÃ
5. רÀûÊÚȨºÅ£ºZL 2013 1 **.0£»×¨ÀûÊÚȨÈÕ£º2014Äê12ÔÂ10ÈÕ£»×¨ÀûÉêÇëºÅ£º**2.0£»×¨ÀûÉêÇëÈÕ£º2013Äê03ÔÂ04ÈÕ£»ÉêÇëÈË£ºÕã½Àí¹¤´óѧ£»·¢Ã÷´´ÔìÃû³Æ£º·ä¶¾¿¹¾úëÄAnoplinÔڸΰ©ÖÎÁÆÖеÄÓÃ;£»·¢Ã÷ÈË£º¸¶²ÊÔÆ£¬Â¬Ñ࣬ÖìÀöÄÈ£¬ÕÔ¸¨À¥£¬ÕÅÊÀ𥡣
6. רÀûÊÚȨºÅ£ºZL 2013 1 **.2£»×¨ÀûÊÚȨÈÕ£º2014Äê12ÔÂ10ÈÕ£»×¨ÀûÉêÇëºÅ£º**6.2£»×¨ÀûÉêÇëÈÕ£º2013Äê03ÔÂ04ÈÕ£»ÉêÇëÈË£ºÕã½Àí¹¤´óѧ£»·¢Ã÷´´ÔìÃû³Æ£º·ä¶¾¿¹¾úëÄAnoplinÔÚѪ°©ÖÎÁÆÖеÄÓÃ;£»·¢Ã÷ÈË£º¸¶²ÊÔÆ£¬Â¬Ñ࣬ÖìÀöÄÈ£¬ÕÔ¸¨À¥£¬ÕÅÊÀ𥡣
7. רÀûÉêÇëºÅ£º**9.6£»×¨ÀûÉêÇëÈÕ£º2014Äê01ÔÂ24ÈÕ£»ÉêÇëÈË£ºÕã½Àí¹¤´óѧ£»·¢Ã÷´´ÔìÃû³Æ£º¹ÑëÄÔÚÖÆ±¸ÓÃÓÚÌá¸ßdelta°¢Æ¬ÊÜÌå±í´ïµÄÒ©ÎïÖеÄÓÃ;£»·¢Ã÷ÈË£º¸¶²ÊÔÆ£¬ÕÅÌÚ·É£¬Â¬Ñ࣬ÏÄÈðÁú¡£
8. רÀûÉêÇëºÅ£º**1.5£»£º2014Äê01ÔÂ24ÈÕ£»ÉêÇëÈË£ºÕã½Àí¹¤´óѧ£»·¢Ã÷´´ÔìÃû³Æ£º¹ÑëÄÁªºÏ»òÓëÄÔ·ÈëĵÄ×éºÏÔÚÖÆ±¸ÓÃÓÚÕòÍ´Ò©ÎïÖеÄÓÃ;£»·¢Ã÷ÈË£º¸¶²ÊÔÆ£¬ÕÅÌÚ·É£¬Â¬Ñ࣬ÏÄÈðÁú¡£
9. רÀûÉêÇëºÅ£º**8.2£»£º2014Äê01ÔÂ24ÈÕ£»ÉêÇëÈË£ºÕã½Ê¡Ò×ÎÄÈüϸ°ûÒ©ÎïºÍÖÆÆ·Ñо¿Ôº£»·¢Ã÷´´ÔìÃû³Æ£ºÒ»ÖÖÓÃÓÚ°©Í´ÖÎÁƵĹÑëÄÁªºÏ»òÓëßßÌæà¤×éºÏµÄ²úÆ·£»·¢Ã÷ÈË£º¸¶²ÊÔÆ£¬Ïî´ºÉú£¬´÷ÁỪ¡£
10. רÀûÉêÇëºÅ£º**4.0£»£º2014Äê01ÔÂ24ÈÕ£»ÉêÇëÈË£ºÕã½Ê¡Ò×ÎÄÈüϸ°ûÒ©ÎïºÍÖÆÆ·Ñо¿Ôº£»·¢Ã÷´´ÔìÃû³Æ£ºÒ»ÖÖÓÃÓÚ°©Í´ÖÎÁƵĹÑëÄÁªºÏ»òÓëÂð·È×éºÏµÄ²úÆ·£»·¢Ã÷ÈË£º¸¶²ÊÔÆ£¬Ïî´ºÉú£¬´÷ÁỪ¡£
11. רÀûÉêÇëºÅ£º**3.2£»×¨ÀûÉêÇëÈÕ£º2016Äê07ÔÂ21ÈÕ£»ÉêÇëÈË£ºÕã½Àí¹¤´óѧ£»·¢Ã÷´´ÔìÃû³Æ£ºÒ»ÖÖ»ùÓÚNK1Rµ°°×µÄ°×Ѫ²¡¼ì²âÊÔ¼ÁºÐ£»·¢Ã÷ÈË£º¸¶²ÊÔÆ£¬Öܺޱ£¬³Â÷裬ʩԽ£¬¸ð³¿ÌΡ£
12. רÀûÉêÇëºÅ£º**1.1£»×¨ÀûÉêÇëÈÕ£º2016Äê09ÔÂ13ÈÕ£»ÉêÇëÈË£ºÕã½Àí¹¤´óѧ£»·¢Ã÷´´ÔìÃû³Æ£ºÒ»ÖÖ»ùÓÚAnnexin A1µ°°×µÄ°×Ѫ²¡¼ì²âÊÔ¼ÁºÐ£»·¢Ã÷ÈË£º¸¶²ÊÔÆ£¬Öܺޱ£¬³Â÷裬ʩԽ£¬¸ð³¿ÌΡ£
ÂÛÎÄ·¢±í
¸¶²ÊÔÆ·¢±íµÄµÚÒ»×÷ÕߺÍͨѶ×÷ÕßÂÛÎÄ£º
18. Zhou HW, Wang X, Chen Q, Ge CT, Shi Y, Fu CY*. Central distribution sites and protein expressions of human HK-1 in mice. International Journal of Clinical and Experimental Pathology, 2017, 10: 5875-5881. (corresponding author)
17. Lu Y, Zhang TF, Shi Y, Zhou HW, Chen Q, Wei BY, Wang X, Yang TX, Chinn YE, Kang J, Fu CY*. PFR peptide, one of the antimicrobial peptides identified from the derivatives of lactoferrin, induces necrosis in leukemia cells. Scientific Reports. 2016, 6: 20823. (corresponding author)
16. Zou Y, Guo CG, Yang ZG, Sun JH, Zhang MM*, Fu CY*. A small interfering RNA targeting vascular endothelial growth factor efficiently inhibits growth of VX2 cells and VX2 tumor model for hepatocellular carcinoma in rabbit by transarterial embolization-mediated siRNA delivery. Drug Design, Development and Terapy, 2016, 10: 1243-1255. (corresponding author)
15. Fang WJ*, Fu CY*, Chen XG, Mou XZ, Liu FL, Qian H, Zhao P, Zheng YL, Zheng Y, Deng J, Ye PJ, Wang YF, Zheng SS. Neurokinin-2 receptor polymorphism predicts lymph node metastasis in colorectal cancer patients. Oncology Letters, 2015, 9: 2003-2006. (co-first anthor)
14. Zhu XC, Zhang JL, Ge CT, Yu YY, Wang P, Yuan TF*, Fu CY*. Advances in cancer pain from bone metastasis. Drug Design, Development and Terapy, 2015, 9: 4239-4245. (corresponding author)
13. Zhu XC, Ge CT, Wang P, Zhang JL, Yu YY, Fu CY*. Analgesic effects of lappaconitine in leukemia bone pain in a mouse model. PeerJ, 2015, 3:e936. (corresponding author)
12. Fu CY*, Xia RL, Zhang TF, Lu Y, Zhang SF, Yu ZQ*, Jin T, Mou XZ*. Hemokinin-1(4-11)-induced analgesia selectively up-regulates ¦Ä-opioid receptor expression in mice. PLoS ONE, 2014, 9(2): e90446. (corresponding author)
11. Fu CY1, Chen W1, Jin YT*. The complete mitochondrial genome of Phrynocephalus guinanensis (Reptilia, Squamata, Agamidae). Mitochondrial DNA£¬2014£¬ 1-2.
10. Xia RL, Lu Y, Zhu LN, Zhang SF, Zhao FK, Fu CY*. Different regulatory pathways are involved in the proliferative inhibition of two types of leukemia cell lines induced by paclitaxel. Oncology Reports, 2013, 30: 1853-1859. (corresponding author)
9. Zhu LN, Fu CY*, Zhang SF, Chen W, Jin YT, Zhao FK. Novel cytotoxic exhibition mode of antimicrobial peptide anoplin in MEL cells, the cell line of murine Friend leukemia virus- induced leukemic cells. Journal of Peptide Science, 2013, 19: 566-574. (corresponding author)
8. Xia RL, Fu CY*, Zhang SF, Jin YT, Zhao FK. Study on the distribution sites and the molecular mechanism of analgesia after intracerebroventricular injection of rat/mouse hemokinin-1 in mice. Peptides, 2013, 43: 113-120. (corresponding author)
7. Fu CY, Zhao YL, Dong L, Chen Q, Ni JM*, Wang R*. In vivo characterization of the effects of human hemokinin-1 and human hemokinin-1(4-11), mammalian tachykinin peptides, on the modulation of pain in mice. Brain, Behavior, and Immunity, 2008, 22: 850-860.
6. Fu CY, Kong ZQ, Long Y, Chen Q, Wang R*. Cardiovascular responses to rat/mouse hemokinin-1, a mammalian tachykinin peptide: Systemic study in anesthetized rats. European Journal of Pharmacology, 2007, 572: 175¨C181.
5. Fu CY, Tang XL, Yang Q, Chen Q, Wang R*. Effects of rat/mouse hemokinin-1, a mammalian tachykinin peptide, on the antinociceptive activity of pethidine administered at the peripheral and supraspinal level. Behavioural Brain Research, 2007, 184: 39¨C46.
4. Fu CY, Yang Q, Wang KR, Kong ZQ, Chen Q, Wang R*. Rat/mouse hemokinin-1, a mammalian tachykinin peptide, markedly potentiates the antinociceptive effects of morphine administered at the peripheral and supraspinal level. Behavioural Brain Research, 2006, 170: 293¨C301.
3. Fu CY, Kong ZQ, Wang KR, Yang Q, Zhai K, Chen Q, Wang R*. Effects and mechanisms of supraspinal administration of rat/mouse hemokinin-1, a mammalian tachykinin peptide, on nociception in mice. Brain Research, 2005, 1056: 51¨C58.
2. Long Y1, Fu CY1, Tian XZ, Chen J, Han M, Wang R*. Mechanisms of relaxing response induced by rat/mouse hemokinin-1 in porcine coronary arteries: Roles of potassium ion and nitric oxide. European Journal of Pharmacology, 2007, 569: 119¨C125. (co-first anthor)
1. Kong ZQ1, Fu CY1, Chen Q, Wang R*. Cardiovascular responses to intravenous administration of human hemokinin-1 and its truncated form hemokinin-1(4-11) in anesthetized rats. European Journal of Pharmacology, 2008, 590: 310¨C316. (co-first anthor)
¸¶²ÊÔÆ²ÎÓë·¢±íµÄÂÛÎÄ£º
8. Chang HN, Liu BY, Qi YK (Qi, Yun-Kun), Zhou Y, Chen YP, Pan KM, Li WW, Zhou XM, Ma WW, Fu CY, Qi YM, Liu L, Gao YF. Blocking of the PD-1/PD-L1 Interaction by a D-Peptide Antagonist for Cancer Immunotherapy. Angewandte Chemie-International Edition, 2015, 54: 11760-11764
7. Fang WJ, Jing DZ, Luo Y, Fu CY, Zhao P, Qian J, Tian BR, Chen XG, Zheng YL, Zheng Y, Deng J, Zou WH, Feng XR, Liu FL, Mou XZ, Zheng SS. Clostridium difficile carriage in hospitalized cancer patients: a prospective investigation in eastern China. BMC Infectious Diseases, 2014, 14:523.
6. Fang WJ, Radovich M, Zheng YL, Fu CY, Zhao P, Mao CY, Zheng Y, Zheng SS. ¡®Druggable¡¯ alterations detected by Ion Torrent in metastatic colorectal cancer patients. Oncology Letters, 2014, 7: 1761-1766.
5. Kong ZQ, Yang WL, Tao Y, Shi XM, Fu CY, Zhao RF, Wang R. Effects of rat/mouse hemokinin-1, human hemokinin-1 and human hemokinin-1(4-11), mammalian tachykinin peptides, on rate and perfusion pressure in the isolated guinea pig heart. Neuropeptides, 2010, 44: 437-444.
4. Kong ZQ, Han M, Yang WL, Zhao YL, Fu CY, Tao Y, Chen Q, Wang R. In vitro characterization of the effects of rat/mouse hemokinin-1 on mouse colonic contractile activity: A comparison with substance P. Neuropeptides, 2009, 43: 213-220.
3. Zhao YL, Tao Y, Fu CY, Kong ZQ, Chen Q, Wang R. Human hemokinin-1 and human hemokinin-1(4¨C11), mammalian tachykinin peptides, suppress proliferation and induce differentiation in HL-60 cells. Peptides, 2009, 30: 1514-1522.
2. Zhai K, Hu L, Chen J, Fu CY, Chen Q. Chrysin induced hyperalgesia via GABAA receptor in mice. Planta Medica, 2008, 74: 1229-1234.
1. Yang Q, Chen Y, Fu CY, Chang M, Peng YL, Wang R. Effects of [Nphe1]nociceptin(1-13)NH2, [Phe1(CH2-NH)Gly2]nociceptin(1-13)NH2, and Nocistatin on Nociceptin Inhibited Constrictions of Guinea Pig Isolated Bronchus. Protein & Peptide Letters, 2006, 131: 85-188.
1.2010Ä꣬»ñÕã½Àí¹¤´óѧ¡°ÓÅÐã°àÖ÷ÈΡ±³ÆºÅ
2.2011Ä꣬»ñÕã½Ê¡µÚÊ®¶þ½ì¡°ÌôÕ½±¡±´óѧÉú¿ÎÍâѧÊõ¿Æ¼¼×÷Æ·¾ºÈüÒ»µÈ½±
3.2011Ä꣬»ñµÚÊ®¶þ½ì¡°ÌôÕ½±¡±È«¹ú´óѧÉú¿ÎÍâѧÊõ¿Æ¼¼×÷Æ·¾ºÈü¶þµÈ½±
4.2011Äָ꣬µ¼±¾¿ÆÉú»ñ2010/2011½ð¸»´º´´Ð´´Òµ½±Ñ§½ð£¨ëÄÆÀÊÀ½çÑ©ÍÅ£¬ÍŶӳÉÔ±ÍõÓîɳ£¬Ó¦Ü·Ü·£¬ÍõÇ¿£¬³ÂÅʷ壬ȫ²¿Îª±¾¿ÆÉú£©
5.2012Ä꣬»ñÕã½Àí¹¤´óѧÉúÃü¿ÆÑ§Ñ§Ôº¿ÆÑй¤×÷Í»³ö¹±Ï×½±
6. 2013Ä꣬»ñµÚÊ®Èý½ì¡°ÌôÕ½±¡±È«¹ú´óѧÉú¿ÎÍâѧÊõ¿Æ¼¼×÷Æ·¾ºÈüÀÛ½ø´´Ð½ð½±
7. 2013Ä꣬»ñÕã½Àí¹¤´óѧ2013½ìÓÅÐã±ÏÒµÂÛÎÄÖ¸µ¼½Ìʦ £¨Ó¦Ü·Ü·£©
8. 2013Äָ꣬µ¼Ñо¿Éú£¨ÏÄÈðÁú£©»ñÖйúҽѧϸ°û·Ö×ÓÉúÎïѧм¼Êõ½øÕ¹Ñ§Êõ±¨¸æ»áôß2013ÄêÕã½Ê¡Ï¸°ûÉúÎïѧѧ»áѧÊõ´ó»áÇàÄêѧÕßÓÅÐã½±
9. 2013Ä꣬»ñÕã½Àí¹¤´óѧÉúÃü¿ÆÑ§Ñ§ÔºÖ¸µ¼±¾¿ÆÉú¿ÆÑй¤×÷»î¶¯ÏȽø¸öÈ˳ƺÅ
10. 2013Ä꣬»ñÕã½Àí¹¤´óѧÉúÃü¿ÆÑ§Ñ§ÔºÓÅÐãѧÍÅÖ¸µ¼½Ìʦ³ÆºÅ
11. 2014Äָ꣬µ¼ÏÄÈðÁú»ñÓÅÐã˶ʿѧλÂÛÎÄ£¨Ð£¼¶£¬2013½ì±ÏÒµÉú£©£¬ÅàÑøÑо¿ÉúÏÄÈðÁú»ñ¡°Õã½Ê¡ÆÕͨ¸ßУÓÅÐã±ÏÒµÉú¡±ÈÙÓþ³ÆºÅ
12. 2014Ä꣬»ñÕã½Àí¹¤´óѧ2014½ìÓÅÐã±ÏÒµÂÛÎÄÖ¸µ¼½Ìʦ £¨ÖÓ˼·É£©
13. 2014Ä꣬Õã½Àí¹¤´óѧ2013Äê¶È¿ÆÐÏȽø¹¤×÷Õß
14. 2014Äָ꣬µ¼±¾¿ÆÉú»ñÕã½Ê¡µÚÁù½ì´óѧÉúÉúÃü¿ÆÑ§¾ºÈüÒ»µÈ½±£¨ÖìÏþ´äµÈ£©
15. 2015Ä꣬»ñÕã½Àí¹¤´óѧ2014Äê¶È½ÌѧÓýÈËÏȽø½±
16. 2015Ä꣬»ñÕã½Àí¹¤´óѧ2015½ìÓÅÐã±ÏÒµÂÛÎÄÖ¸µ¼½Ìʦ £¨Ê©Ô½£©
17. 2015Ä꣬»ñ2014ÄêÕã½Àí¹¤´óѧÉúÃü¿ÆÑ§Ñ§ÔºÓÅÐãÑо¿ÉúÖ¸µ¼½Ìʦ
18. 2015Ä꣬»ñ2014ÄêÕã½Àí¹¤´óѧÉúÃü¿ÆÑ§Ñ§Ôº¿ÆÑй¤×÷ÏȽø¸öÈËÈÙÓþ³ÆºÅ
19. 2015Äָ꣬µ¼±¾¿ÆÉú»ñÕã½Àí¹¤´óѧ¡°ÌôÕ½±¡±´óѧÉú¿ÎÍâѧÊõ¿Æ¼¼×÷Æ·¾ºÈüÌØµÈ½±
20. 2015Ä꣬ Ö¸µ¼±¾¿ÆÉú»ñÕã½Ê¡µÚÊ®ËĽ조ÌôÕ½±¡±´óѧÉú¿ÎÍâѧÊõ¿Æ¼¼×÷Æ·¾ºÈüÒ»µÈ½±
21. 2015Ä꣬ Ö¸µ¼±¾¿ÆÉú»ñµÚÊ®ËÄ¡°ÌôÕ½±¡±È«¹ú´óѧÉú¿ÎÍâѧÊõ¿Æ¼¼×÷Æ·¾ºÈü¶þµÈ½±
22. 2015Äָ꣬µ¼±¾¿ÆÉú»ñµÚÊ®ËÄ¡°ÌôÕ½±¡±È«¹ú´óѧÉú¿ÎÍâѧÊõ¿Æ¼¼×÷Æ·¾ºÈüÀÛ½ø´´ÐÂÒø½±
23. 2015Äָ꣬µ¼±¾¿ÆÉú»ñ2014/2015ѧÄê½ð¸»´º´´Ð´´Òµ½±Ñ§½ð£¨ëÄÆÀÊÀ½çѧÍÅ£¬ÍŶӳÉÔ±ÖìÏþ´ä¡¢ÕżÑÀö¡¢¸ð³¿ÌΡ¢ÍõÅΡ¢ÓÚÔ¶Ñó£©
24. 2015Ä꣬Õã½Ê¡×ª»¯Ò½Ñ§Ñ§»áÓÅÐãÀíÊÂ
25. 2015Äָ꣬µ¼Â¬Ñà»ñÓÅÐã˶ʿѧλÂÛÎÄ£¨Ð£¼¶£¬2014½ì±ÏÒµÉú£©
26. 2016Ä꣬»ñÕã½Àí¹¤´óѧ2016½ìÓÅÐã±ÏÒµÂÛÎÄÖ¸µ¼½Ìʦ £¨ÓÚÔ¶Ñó£©
27. 2016Äָ꣬µ¼ÕÅÌÚ·É»ñÓÅÐã˶ʿѧλÂÛÎÄ£¨Ð£¼¶£¬2015½ì±ÏÒµÉú£©
28. 2016Ä꣬»ñ½ÌÓý²¿°ä·¢µÄ»ôÓ¢¶«½ÌÓý»ù½ð»áµÚÊ®Îå½ì¸ßµÈԺУÇàÄê½Ìʦ½±
29. 2016Äָ꣬µ¼±¾¿ÆÉú»ñÕã½Ê¡µÚ°Ë½ì´óѧÉúÉúÃü¿ÆÑ§¾ºÈü¶þµÈ½±£¨ÃÉÔÂÃ÷µÈ£©
30. 2016Ä꣬»ñÕã½Àí¹¤´óѧÉúÃü¿ÆÑ§Ñ§ÔºµÚÊ®½ìÇàÄê½Ìʦ½²¿Î±ÈÈü¶þµÈ½±
ÄâÿÄêÕÐÊÕ1-2Ãû˶ʿÉú£¬»¶Óϸ°ûÉúÎïѧ¡¢ÉúÎﻯѧÓë·Ö×ÓÉúÎïѧÏà¹ØöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£¬²¢¶Ô¿ÆÑи»ÓÐŨºñÐËȤµÄ¿¼Éú±¨¿¼¡£
Õã½Àí¹¤´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-¸¶²ÊÔÆ
±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø/2019-05-27
Ïà¹Ø»°Ìâ/Õã½Àí¹¤´óѧ ÅÅÃû ÊÚȨ ÓÅÐã ѧÊõ
Õã½Àí¹¤´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-Ò¦¾ÕÃ÷
µ¼Ê¦ÐÕÃû£ºÒ¦¾ÕÃ÷ÐÔ±ð£ºÄÐÈËÆøÖ¸Êý£º528ËùÊôԺУ£ºÕã½Àí¹¤´óѧËùÊôԺϵ£º²ÄÁÏÓë·Ä֯ѧԺְ³Æ£º½ÌÊÚµ¼Ê¦ÀàÐÍ£ºÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£º²ÄÁϹ¤³Ì¡¢²ÄÁÏ¿ÆÑ§Ó빤³Ì¡¢·ÄÖ¯¿ÆÑ§Ó빤³ÌÑо¿ÁìÓò£ºÉúÎï¸ß·Ö×Ó£¨µ°°×ÖÊ¡¢ÏËÎ¬ËØ£©²ÄÁϵŦÄÜ»¯ÀûÓ㬹¦ÄÜÐÔÏËάÓë·Ä֯Ʒ¡£Ñо¿ÁìÓò£ºÉúÎï¸ß·Ö×Ó£¨µ°°×ÖÊ¡¢ÏËÎ¬ËØ£©²ÄÁϵŦÄÜ»¯ÀûÓ㬹¦ÄÜÐÔÏËάÓë ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27Õã½Àí¹¤´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-ÕÔÑ©ÇÛ
µ¼Ê¦ÐÕÃû£ºÕÔÑ©ÇÛÐÔ±ð£ºÅ®ÈËÆøÖ¸Êý£º527ËùÊôԺУ£ºÕã½Àí¹¤´óѧËùÊôԺϵ£ºÉúÃü¿ÆÑ§Ñ§ÔºÖ°³Æ£º½²Ê¦µ¼Ê¦ÀàÐÍ£ºÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÉúÎïѧÑо¿ÁìÓò£º1.·Ç²¡¶¾ÔØÌåµÄ»ùÒò³ÁĬ2.×éÖ¯¹¤³ÌÖ§¼Ü¼°Ï¸°û-Í¿²ã½çÃæÐ§Ó¦3.º£Ñóµ°°×ÖʵĹ̶¨»¯¼°Ð§¹ûÑÐ...[Õ¹¿ª]Ñо¿ÁìÓò£º1.·Ç²¡¶¾ÔØÌåµÄ»ùÒò³ÁĬ2.×éÖ¯¹¤³ÌÖ§¼Ü¼°Ï¸°û-Í¿²ã½çÃæ ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27Õã½Àí¹¤´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-Ò¶·É
µ¼Ê¦ÐÕÃû£ºÒ¶·ÉÐÔ±ð£ºÅ®ÈËÆøÖ¸Êý£º526ËùÊôԺУ£ºÕã½Àí¹¤´óѧËùÊôԺϵ£ºÉúÃü¿ÆÑ§Ñ§ÔºÖ°³Æ£º½²Ê¦µ¼Ê¦ÀàÐÍ£ºÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÉúÎïѧÑо¿ÁìÓò£º£º£¨1£©¼ÆËã»ú¸¨ÖúÒ©Îï·¢ÏÖÓëÉè¼Æ£¬ÔËÓÃÒ©ÎïÉè¼Æ·½·¨Õë¶Ô¶àÖÖÉúÎï°Ð±ê£¬½áºÏʵÑéÑéÖ¤£¬·¢ÏÖ»îÐÔ...[Õ¹¿ª]Ñо¿ÁìÓò£º£º£¨1£©¼ÆËã»ú¸¨ÖúÒ©Îï·¢ÏÖÓëÉè¼Æ£¬ÔËÓÃÒ©ÎïÉè¼Æ·½·¨Õë¶Ô¶àÖÖ ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27Õã½Àí¹¤´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-ºú¾õÁÁ
µ¼Ê¦ÐÕÃû£ººú¾õÁÁÐÔ±ð£ºÄÐÈËÆøÖ¸Êý£º526ËùÊôԺУ£ºÕã½Àí¹¤´óѧËùÊôԺϵ£ºÀíѧԺְ³Æ£º½ÌÊÚµ¼Ê¦ÀàÐÍ£ºÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÊýѧ¡¢Èí¼þ¹¤³Ì¡¢·ÄÖ¯¿ÆÑ§Ó빤³ÌÑо¿ÁìÓò£º×éºÏÓÅ»¯£»Ëã·¨Éè¼ÆÓë·ÖÎö£»·þ×°Éú²úÁ÷³ÌÓ빩ӦÁ´¹ÜÀíÑо¿ÁìÓò£º×éºÏÓÅ»¯£»Ëã·¨Éè¼ÆÓë·ÖÎö£»·þ×°Éú²úÁ÷³ÌÓ빩ӦÁ´¹ÜÀí[ÊÕÆð]ͨѶ·½Ê½:°ì¹«µç»°£º**ͨѶµØÖ·£º ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27Õã½Àí¹¤´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-³Ì¸Õ
µ¼Ê¦ÐÕÃû£º³Ì¸ÕÐÔ±ð£ºÄÐÈËÆøÖ¸Êý£º522ËùÊôԺУ£ºÕã½Àí¹¤´óѧËùÊôԺϵ£ºÂí¿Ë˼Ö÷ÒåѧԺְ³Æ£º½ÌÊÚµ¼Ê¦ÀàÐÍ£ºÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÂí¿Ë˼Ö÷ÒåÀíÂÛÑо¿ÁìÓò£º´óѧÉú˼ÏëÕþÖνÌÓý¡¢¸ßУУ԰ÎÄ»¯µÈ¡£Ñо¿ÁìÓò£º´óѧÉú˼ÏëÕþÖνÌÓý¡¢¸ßУУ԰ÎÄ»¯µÈ¡£[ÊÕÆð]ͨѶ·½Ê½:°ì¹«µç»°£º**ͨѶµØÖ·£ºÕã½Ê¡º¼ÖÝÊÐÏÂɳ¸ß½ÌÔ°ÇøÕã½Àí¹¤´óѧµ³ ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27Õã½Àí¹¤´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-ÀîÈÊÍú
µ¼Ê¦ÐÕÃû£ºÀîÈÊÍúÐÔ±ð£ºÄÐÈËÆøÖ¸Êý£º523ËùÊôԺУ£ºÕã½Àí¹¤´óѧËùÊôԺϵ£º»úеÓë×Ô¶¯¿ØÖÆÑ§ÔºÖ°³Æ£º½ÌÊÚµ¼Ê¦ÀàÐÍ£ºÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£º»úе¹¤³ÌÑо¿ÁìÓò£º·½Ïò1£ºÖÆÔìÒµÐÅÏ¢»¯l·½Ïò2£º²úÆ·Éè¼ÆÓë²úÆ·½¨Ä£¼¼Êõl·½Ïò3£ºÆóÑо¿ÁìÓò£º·½Ïò1£ºÖÆÔìÒµÐÅÏ¢»¯l·½Ïò2£º²úÆ·Éè¼ÆÓë²úÆ·½¨Ä£¼¼Êõl·½Ïò3£ºÆó[ÊÕÆð]ͨѶ·½Ê½:°ì¹«µç ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27Õã½Àí¹¤´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-³Â
µ¼Ê¦ÐÕÃû£º³ÂÐÔ±ð£ºÄÐÈËÆøÖ¸Êý£º520ËùÊôԺУ£ºÕã½Àí¹¤´óѧËùÊôԺϵ£ºÀíѧԺְ³Æ£º½²Ê¦µ¼Ê¦ÀàÐÍ£ºÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£º»¯Ñ§Ñо¿ÁìÓò£ºÒ»¹ý¶É½ðÊô´ß»¯µÄ̼Çâ¹ÙÄÜ»¯·´Ó¦¶þ¹ý¶É½ðÊô»ò·Ç½ðÊô´Ù½øµÄº¬µªÔÓ»·»¯ºÏÎïºÏ³ÉÑо¿ÁìÓò£ºÒ»¹ý¶É½ðÊô´ß»¯µÄ̼Çâ¹ÙÄÜ»¯·´Ó¦¶þ¹ý¶É½ðÊô»ò·Ç½ðÊô´Ù½øµÄº¬µªÔÓ»·»¯ºÏÎïºÏ³É[ÊÕÆð]ͨѶ·½Ê½:°ì¹«µç ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27Õã½Àí¹¤´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-º«±øÄÐ
µ¼Ê¦ÐÕÃû£ºº«±øÄÐÐÔ±ð£ºÄÐÈËÆøÖ¸Êý£º519ËùÊôԺУ£ºÕã½Àí¹¤´óѧËùÊôԺϵ£ºÉúÃü¿ÆÑ§Ñ§ÔºÖ°³Æ£ºÑо¿Ô±µ¼Ê¦ÀàÐÍ£ºÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÉúÎïѧÑо¿ÁìÓò£ºÖ÷Òª´Óʺ£ÑóÉúÎï»îÐÔÎïÖʵķÖÀëÌáÈ¡£¬½á¹¹¼ø¶¨ºÍ¹¹Ð§¹ØÏµ£¬ÒÔ¼°»îÐÔ·Ö×ÓµÄϵͳÉúÎïѧÑо¿¡£Ñо¿ÁìÓò£ºÖ÷Òª´Óʺ£ÑóÉúÎï»îÐÔÎïÖʵķÖÀëÌáÈ¡£¬½á¹¹¼ø¶¨ºÍ¹¹Ð§¹ØÏµ£¬ÒÔ¼°»îÐÔ·Ö×ÓµÄϵ ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27Õã½Àí¹¤´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-½ð±Ì»ª
µ¼Ê¦ÐÕÃû£º½ð±Ì»ªÐÔ±ð£ºÄÐÈËÆøÖ¸Êý£º517ËùÊôԺУ£ºÕã½Àí¹¤´óѧËùÊôԺϵ£º·¨ÕþѧԺְ³Æ£º¸±½ÌÊÚµ¼Ê¦ÀàÐÍ£ºÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÂí¿Ë˼Ö÷ÒåÀíÂÛ¡¢·¨ÂÉÑо¿ÁìÓò£º£¨1£©·¨ÂÉÉç»áѧ£¨2£©Éç»á¹¤×÷ÓëÉç»á×éÖ¯Ñо¿ÁìÓò£º£¨1£©·¨ÂÉÉç»áѧ£¨2£©Éç»á¹¤×÷ÓëÉç»á×éÖ¯[ÊÕÆð]ͨѶ·½Ê½:°ì¹«µç»°£º**ͨѶµØÖ·£ºÕã½Àí¹¤´óѧ·¨ÕþѧԺ¸öÈ˼ò ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27Õã½Àí¹¤´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-½¯²ÊÓ¢
µ¼Ê¦ÐÕÃû£º½¯²ÊÓ¢ÐÔ±ð£ºÄÐÈËÆøÖ¸Êý£º514ËùÊôԺУ£ºÕã½Àí¹¤´óѧËùÊôԺϵ£ºÉúÃü¿ÆÑ§Ñ§ÔºÖ°³Æ£º¸±Ñо¿Ô±µ¼Ê¦ÀàÐÍ£ºÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÉúÎïѧÑо¿ÁìÓò£ºÀ¥³æÉúÀíÉú»¯Óë·Ö×ÓÉúÎïѧÑо¿ÁìÓò£ºÀ¥³æÉúÀíÉú»¯Óë·Ö×ÓÉúÎïѧ[ÊÕÆð]ͨѶ·½Ê½:°ì¹«µç»°£º**ͨѶµØÖ·£ºÕã½Ê¡º¼ÖÝÊÐÏÂɳ¸ß½ÌÔ°Çø2ºÅ´ó½Ö928ºÅ¸öÈ˼òÊö:½¯²ÊÓ¢²©Ê¿£¬¸±ÑÐ ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27Õã½Àí¹¤´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-±«Ãô
µ¼Ê¦ÐÕÃû£º±«ÃôÐÔ±ð£ºÄÐÈËÆøÖ¸Êý£º512ËùÊôԺУ£ºÕã½Àí¹¤´óѧËùÊôԺϵ£º»úеÓë×Ô¶¯¿ØÖÆÑ§ÔºÖ°³Æ£º¸±½ÌÊÚµ¼Ê¦ÀàÐÍ£ºÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£º»úе¹¤³ÌÑо¿ÁìÓò£º£¨1£©Á÷Á¿ÒÇ±í£ºÒÔÊý×ÖÐźŴ¦ÀíÆ÷ºÍÆäËûǶÈëʽоƬΪºËÐÄ£¬ÊµÏÖ¶ÔÁ÷¶¯ÐźŵIJɼ¯¡¢´¦Àí¡£²ÎÓëµÄ...[Õ¹¿ª]Ñо¿ÁìÓò£º£¨1£©Á÷Á¿ÒÇ±í£ºÒÔÊý×ÖÐźŴ¦ÀíÆ÷ºÍÆäËûǶÈëʽоƬ ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27Õã½Àí¹¤´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-ÀîÃ÷
µ¼Ê¦ÐÕÃû£ºÀîÃ÷ÐÔ±ð£ºÄÐÈËÆøÖ¸Êý£º511ËùÊôԺУ£ºÕã½Àí¹¤´óѧËùÊôԺϵ£ºÒÕÊõÓëÉè¼ÆÑ§ÔºÖ°³Æ£º½ÌÊÚµ¼Ê¦ÀàÐÍ£ºÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÉè¼ÆÑ§¡¢ÃÀÊõ¡¢ÒÕÊõÉè¼Æ¡¢ÃÀÊõѧÑо¿ÁìÓò£ºÉÌÒµ²å»¹ú»Ñо¿ÁìÓò£ºÉÌÒµ²å»¹ú»[ÊÕÆð]ͨѶ·½Ê½:°ì¹«µç»°£º**ͨѶµØÖ·£ºÕã½Ê¡º¼ÖÝÊÐÏÂɳÕã½Àí¹¤´óѧÒÕÊõÓëÉè¼ÆÑ§Ôº¸öÈ˼òÊö:ÀîÃ÷ºþÄÏÊ¡³¤É³ÊÐÈË ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27Õã½Àí¹¤´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-ÐìÇà
µ¼Ê¦ÐÕÃû£ºÐìÇàÐÔ±ð£ºÅ®ÈËÆøÖ¸Êý£º507ËùÊôԺУ£ºÕã½Àí¹¤´óѧËùÊôԺϵ£ºÍâ¹úÓïѧԺְ³Æ£º¸±½ÌÊÚµ¼Ê¦ÀàÐÍ£ºÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£º·ÒëÑо¿ÁìÓò£º½üÏÖ´úÖÐÈÕ·Òë¡¢ÖÐÈÕÎÄ»¯½»Á÷Ê·¡¢ÖÐÈÕÎÄ»¯¹ØÏµÂÛ¡¢½üÏÖ´úÈÕ±¾±È½ÏÎÄѧ¡¢ÎÄ»¯µÈÑо¿ÁìÓò£º½üÏÖ´úÖÐÈÕ·Òë¡¢ÖÐÈÕÎÄ»¯½»Á÷Ê·¡¢ÖÐÈÕÎÄ»¯¹ØÏµÂÛ¡¢½üÏÖ´úÈÕ±¾±È½ÏÎÄѧ¡¢ÎÄ»¯µÈ[ÊÕÆð]ͨѶ·½Ê½ ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27Õã½Àí¹¤´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-ÕÅÐã÷
µ¼Ê¦ÐÕÃû£ºÕÅÐã÷ÐÔ±ð£ºÅ®ÈËÆøÖ¸Êý£º506ËùÊôԺУ£ºÕã½Àí¹¤´óѧËùÊôԺϵ£º²ÄÁÏÓë·Ä֯ѧԺְ³Æ£º¸±½ÌÊÚµ¼Ê¦ÀàÐÍ£ºÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÇṤ¼¼ÊõÓ빤³Ì¡¢²ÄÁÏ¿ÆÑ§Ó빤³ÌÑо¿ÁìÓò£ºÔìֽʪ²¿»¯Ñ§¿ØÖÆ¡¢ÔìÖ½»¯Ñ§Æ·µÄºÏ³ÉÓëÓ¦Óá¢Ä¾²ÄµÄ»¯Ñ§³É·Ö·ÖÎöÓëÖÆ½¬ÐÔÄÜ¡¢Ä¾ÖÊËØµÄ»¯Ñ§½µ½âÓë...[Õ¹¿ª]Ñо¿ÁìÓò£ºÔìֽʪ²¿»¯Ñ§¿ØÖÆ¡¢ÔìÖ½»¯Ñ§Æ· ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27Õã½Àí¹¤´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-ÕÅÎÄÆ½
µ¼Ê¦ÐÕÃû£ºÕÅÎÄÆ½ÐÔ±ð£ºÄÐÈËÆøÖ¸Êý£º505ËùÊôԺУ£ºÕã½Àí¹¤´óѧËùÊôԺϵ£ºÉúÃü¿ÆÑ§Ñ§ÔºÖ°³Æ£º¸±½ÌÊÚµ¼Ê¦ÀàÐÍ£ºÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÉúÎïѧÑо¿ÁìÓò£º1¡¢Éñ¾ºÍϸ°ûÉúÎïѧ2¡¢Éñ¾Ò©Àíѧ3¡¢ÉúÎï¼¼ÊõÒ©ÎïÑз¢Ñо¿ÁìÓò£º1¡¢Éñ¾ºÍϸ°ûÉúÎïѧ2¡¢Éñ¾Ò©Àíѧ3¡¢ÉúÎï¼¼ÊõÒ©ÎïÑз¢[ÊÕÆð]ͨѶ·½Ê½:°ì¹«µç»°£º**ͨѶµØÖ·£ºÕã½Àí¹¤ ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27
